Core Insights - Akero Therapeutics is a clinical-stage company focused on developing treatments for serious metabolic diseases with high unmet medical needs, particularly MASH [2] Group 1: Company Overview - Akero's lead product candidate, EFX, is currently being evaluated in three ongoing Phase 3 clinical trials targeting patients with pre-cirrhotic MASH (F2-F3) and compensated cirrhosis (F4) due to MASH [2] - The SYNCHRONY program builds on the results of two Phase 2b clinical trials, including the completed HARMONY study and the ongoing SYMMETRY study, with over 300 patients treated with EFX or placebo for up to 96 weeks [2] - The company is headquartered in South San Francisco and provides additional information through its website and social media platforms [2] Group 2: Upcoming Events - Management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 11:15 a.m. P.T. [1] - A live webcast of the presentation will be available on the company's investor relations section, with an archived replay accessible afterward [1]

-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage (conventional histopathology), (2) 30% reduction of liver stiffness by FibroScan® (imaging fibrosis biomarker), and (3) 0.5 point decrease in ELFTM score (serum fibrosis biomarker) – -- Analysis of biopsies by AI-based Digital Pathology (qFibrosis®, Histoindex) corroborated the extent of impr ...

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 12:00 p.m. GMT. A live webcast of the Company presentation will be available through the investor relations section ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38944 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-5266573 (State or ...

Exhibit 99.1 akEro Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update — First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — Phase 3 SYNCHRONY Real-World and Histology studies on track to report results for their respective primary endpoints in 2026 and the first half of 2027 — — Phase 2b SYMMETRY study week 96 results expected to readout in February 2025 — SOUTH SAN F ...

— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — — Phase 3 SYNCHRONY Real-World and Histology studies on track to report results for their respective primary endpoints in 2026 and the first half of 2027 — — Phase 2b SYMMETRY study week 96 results expected to readout in February 2025 — SOUTH SAN FRANCISCO, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage ...

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced an upcoming oral presentation and two late-breaking poster presentations at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 taking place from November 15-19, 2024, in San Diego. The presentations ...

Group 1 - Moore Law, PLLC is investigating potential claims against Akero Therapeutics, Inc. regarding misrepresentations about the patient population in the SYMMETRY study [1] - The investigation highlights that approximately 20% of the tested patients had not confirmed NASH as the cause of their cirrhosis, which is critical for data integrity [1] - Akero's stock price fell by $30.39 per share, or 62.61%, closing at $18.15 per share following disappointing interim data from the Phase 2b SYMMETRY trial [2] Group 2 - In the SYMMETRY trial, only 22% (28mg) and 24% (50mg) of patients on EFX showed at least one stage improvement in fibrosis, with no worsening of NASH, but these results were not statistically significant [2] - The trial faced issues with patient discontinuation, with 12 patients, including 11 from EFX groups, dropping out due to drug-related adverse events [2]

I covered Akero Therapeutics (NASDAQ: AKRO ) in May last year when we were awaiting data from the phase 2b SYMMETRY study. Since then, two events negative for the stock have taken place. One, poor SYMMETRY data, and two, Madrigal’s (About the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material.  ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38944 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-5266573 (State or othe ...